Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
CMXI > SEC Filings for CMXI > Form 8-K on 11-Apr-2014All Recent SEC Filings

Show all filings for CYTOMEDIX INC

Form 8-K for CYTOMEDIX INC


11-Apr-2014

Change in Directors or Principal Officers


Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers; Compensatory Arrangements of Certain Officers

(e) On April 8, 2014, following the Compensation Committee's recommendation, the Board of Directors (the "Board") of Cytomedix, Inc. (the "Company") approved an amendment to the Company's 2013 Equity Compensation Plan (adopted by the Company's shareholders in December 2013) (the "Plan") which increased the number of authorized shares under the Plan from 3,000,000 to 18,000,000 shares, subject to shareholder approval. In addition, the Board also approved the following grants of options to purchase shares of the Company's common stock under the Company's 2013 Equity Compensation Plan, subject to authorized share availability:

  Name/Office                                 Number of Options (1):
  Martin P. Rosendale, CEO                    2,624,800
  Steven A. Shallcross, CFO, Executive VP (2) 1,219,900
  Edward Field, COO                           1,285,900
  Dean Tozer, CCO (3)                         1,540,800
  Peter Clausen, CSO                          1,311,600

(1) The subject options vest over four year vesting period, with the vesting period commencing twelve months from the grant date where one quarter will vest and the remainder of subject options vesting in equal monthly increments over the period of thirty six months following such date. The exercise price of the subject options was $0.60 per share, the closing price of the Company's common stock on the grant date.

(2) In recognition for his services, the Board approved a one-time cash bonus in the amount of $60,000 payable to Mr. Shallcross.

(3) The subject options vest over three year vesting period, with the vesting period commencing twelve months from the grant date when one third of such options will vest and the remainder of the subject options vesting in equal monthly increments over the period of twenty four months following such date. The exercise price of the subject options was $0.60 per share, the closing price of the Company's common stock on the grant date.

Item 9.01 Exhibits

NA.

  Add CMXI to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for CMXI - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.